Insights into Insulin Treatment Challenges: Real-World Evidence and Clinical Trial Data

Introduction/Background

Timely* Application of Insulin Therapy in T2DM

Dangers of Delayed Insulin Initiation

Patient Attitudes Toward Insulin: Fears and Misperceptions

Insulin, Clinical Inertia, and the Burden of Time Constraints

Delays in Therapeutic Intensification

Clinical Impact of T2DM

Insulin Therapy and the Severely Insulin-Resistant Patient[a,b]

Issues With Adherence and Persistence

Medication Errors May Be Associated With Greater Insulin Use

Complexity-of-Regimen Issues

U-500R: Treating the Severely Insulin-Resistant Patient With Long-Standing T2DM

What Is Clinical Inertia?

DAWN2 Results: Deficiencies in Communication and Education

MOSAIc Study: Associations Among Patient-Physician Interactions, T2DM-Related Distress, Insulin Adherence, and HbA1c

MOSAIc Study: Key Findings

Discrepancies Between Patients’ and Providers’ Perspectives on Medication Nonadherence: Qualitative Meta-Synthesis

U-500R Thrice Daily vs Twice Daily: Actual and CFB TDD Values

U-500R Thrice Daily vs Twice Daily: Body Weight CFB

EDITION 3: Comparison of IGlar 300 U/mL vs IGlar 100 U/mL in Insulin-Naive Patients

BEGIN LOW VOLUME: IDeg 200 U/mL Once Daily Compared With IGlar

Insulin Initiation and Titration Suggestions for T2DM: Canadian Diabetes Association

Results From the AUTONOMY Study

Autonomy, AUTONOMY, and Adherence

Conclusions

Abbreviations